BioNeutra Global Corporation
BGACF
$0.067
$0.006911.48%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.35% | -17.54% | -17.62% | 4.26% | -25.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.35% | -17.54% | -17.62% | 4.26% | -25.00% |
| Cost of Revenue | 32.30% | -35.03% | -25.32% | -92.59% | -34.91% |
| Gross Profit | -7.34% | 106.48% | 34.05% | 611.42% | 4.23% |
| SG&A Expenses | -9.88% | 23.42% | 3.35% | -3.15% | -10.24% |
| Depreciation & Amortization | -6.38% | -26.39% | 0.00% | -36.82% | 39.60% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.49% | -16.60% | -16.64% | -63.78% | -25.37% |
| Operating Income | 21.61% | 13.71% | 12.72% | 150.83% | 27.95% |
| Income Before Tax | 69.65% | 40.00% | 9.68% | 214.71% | -5.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.65% | 40.00% | 9.68% | 214.71% | -5.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.65% | 40.00% | 9.68% | 214.71% | -5.54% |
| EBIT | 21.61% | 13.71% | 12.72% | 150.83% | 27.95% |
| EBITDA | -197.69% | 14.74% | 13.36% | 175.77% | 64.55% |
| EPS Basic | 69.63% | 40.20% | 9.52% | 216.67% | -5.42% |
| Normalized Basic EPS | 28.07% | 17.74% | 9.78% | 180.83% | 55.12% |
| EPS Diluted | 67.41% | 34.53% | 0.00% | 179.17% | 2.61% |
| Normalized Diluted EPS | 28.07% | 17.74% | 9.78% | 180.83% | 55.12% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | -1.61% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | -1.61% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
